Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 5—May 2023
Dispatch

Limited Nosocomial Transmission of Drug-Resistant Tuberculosis, Moldova

Ecaterina Noroc1, Dumitru Chesov1, Matthias Merker1, Matthias I. Gröschel, Ivan Barilar, Viola Dreyer, Nelly Ciobanu, Maja Reimann, Valeriu Crudu, and Christoph LangeComments to Author 
Author affiliations: Chiril Draganiuc Phthisiopneumology Institute, Chisinau, Moldova (E. Noroc, N. Ciobanu, V. Crudu); Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau (D. Chesov); Research Center Borstel, Borstel, Germany (D. Chesov, M. Merker, I. Barilar, V. Dreyer, M. Reimann, C. Lange); German Center for Infection Research (DZIF), Borstel (M. Merker, I. Barilar, V. Dreyer, M. Reimann, C. Lange); Harvard Medical School, Boston, Massachusetts, USA (M.I. Gröschel); Charité–Universitätsmedizin Berlin, Berlin, Germany (M.I. Gröschel); University of Lübeck, Lübeck, Germany (M. Reimann, C. Lange); Baylor College of Medicine and Texas Children’s Hospital, Houston, Texas, USA (C. Lange)

Main Article

Table 1

Characteristics of patients by hospital departments in study of limited nosocomial transmission of drug-resistant TB, Moldova*

Characteristic Total, 
n = 2,490 Dept 1, 
n = 401 Dept 2, 
n = 445 Dept 3, 
n = 1,127 MDR TB dept, n = 156 EP-TB and Surgery dept, n = 361
Mean age, y (+SD)
 50.9 (+17.4)
 43.7 (+13.8)
 45.6 (+12.1)
 59.4 (+17.5)
 37.2 (+12.7)
 45.2 (+15.4)
Sex
M 1,623 (65.2) 288 (71.8) 356 (80.0) 609 (54.0) 110 (70.5) 260 (72.0)
F
 867 (34.8)
 113 (28.2)
 89 (20.0)
 518 (46.0)
 46 (29.5)
 101 (28.0)
TB 1,379 (55.4) 397 (99) 442 (99.3) 57 (5,1) 156 (100) 327 (90.6)
Culture positive TB 938 (68.0) 296 (74.6) 331 (74.9) 25 (43.9) 142 (91) 144 (44.0)
Culture negative or missed TB, 
Xpert positive 78 (5.7) 20 (5.0) 27 (6.1) 8 (14.0) 9 (5.8) 14 (4.3)
Patients without microbiological 
confirmation of TB 363 (26.3) 81 (20.4) 84 (19.5) 24 (42.9) 5 (3.2) 169 (51.7)
MDR TB by culture 307 (31.4) 39 (11.5) 77 (21.3) 7 (25) 141 (99.3) 43 (29.2)
New TB cases 1,034 (75) 380 (95.7) 259 (58.6) 52 (91.2) 82 (52.6) 261 (79.8)
Relapse TB 233 (16.9) 16 (4.0) 135 (30.5) 5 (8.9) 30 (19.2) 47 (14.4)
Retreatment after LTF 50 (3.6) 1 (0.3) 23 (5.2) 0 15 (9.6) 11 (3.4)
Retreatment after failure 62 (4.5) 0 25 (5.7) 0 29 (18.6) 8 (2.5)
Pulmonary TB 1,114 (80.8) 369 (92.9) 425 (96.2) 44 (77.2) 149 (95.5) 127 (38.8)
Extrapulmonary TB 183 (13.3) 8 (2) 3 (0.7) 11 (19.6) 1 (0.6) 160 (49)
Pulmonary and extrapulmonary TB 82 (5.9) 20 (5.5) 14 (3.2) 2 (3.6) 6 (3.9) 40 (12.2)

*Values are no. (%) except as indicated. Xpert, Xpert MTB/RIF assay (Cepheid, https://www.cepheid.com). Dept, department; EP-TB, extrapulmonary TB; LTF, loss to follow-up; MDR, multidrug-resistant; TB, tuberculosis.

Main Article

1These first authors contributed equally to this article.

Page created: March 17, 2023
Page updated: April 19, 2023
Page reviewed: April 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external